HERTFORDSHIRE, England and PITTSBURGH, May 23, 2016 /PRNewswire/ -- Mylan N.V. (Nasdaq:
Doxycycline Hyclate DR Tablets USP, 200 mg, had U.S. sales of approximately $181.8 million for the 12 months ending March 31, 2016, according to IMS Health.
Currently, Mylan has 258 ANDAs pending FDA approval representing $109 billion in annual brand sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $37.4 billion in annual brand sales, for the 12 months ending December 31, 2015, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our nearly 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylan-launches-first-generic-doryx-delayed-release-tablets-200-mg-300272372.html
SOURCE Mylan N.V.
Subscribe to our Free Newsletters!
Endoscopic Retrograde Cholangio-Pancreatography uses endoscopy and fluoroscopic imaging for ...
Wolff-Parkinson-White syndrome is caused due to an extra electrical pathway in the heart, which ...
Discover the amazing health benefits of this ''under-valued'' vegetable called leek. Know the ...View All